Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZM008 as Single Agent Followed by Combination With Toripalimab in Advanced Solid Tumors
NCT06451497Phase 1Recruiting
- Sponsor
- Zumutor Biologics
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ZM008 in solid tumor, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 9 more, sponsored by Zumutor Biologics. Primary endpoints: Dose Limiting Toxicities, Change in systolic and diastolic Blood Pressure and 3 more. Started May 2024; status: recruiting.
02
Drugs
ZM008
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)pancreatic adenocarcinoma (PDAC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06451497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06451497.